These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30727869)

  • 1. Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins.
    Tan H; Su W; Zhang W; Wang P; Sattler M; Zou P
    Curr Pharm Des; 2018; 24(41):4932-4946. PubMed ID: 30727869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-life extended biotherapeutics.
    Kontermann RE
    Expert Opin Biol Ther; 2016 Jul; 16(7):903-15. PubMed ID: 26967759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins.
    Khodabakhsh F; Salimian M; Hedayati MH; Ahangari Cohan R; Norouzian D
    Prep Biochem Biotechnol; 2021; 51(6):519-529. PubMed ID: 33459157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.
    van Witteloostuijn SB; Pedersen SL; Jensen KJ
    ChemMedChem; 2016 Nov; 11(22):2474-2495. PubMed ID: 27775236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments.
    Wang L; Ying T
    Curr Pharm Biotechnol; 2016; 17(15):1348-1352. PubMed ID: 27552847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension.
    Cho J; Park J; Tae G; Jin MS; Kwon I
    Biomedicines; 2020 Apr; 8(5):. PubMed ID: 32357510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current strategies in extending half-lives of therapeutic proteins.
    Zaman R; Islam RA; Ibnat N; Othman I; Zaini A; Lee CY; Chowdhury EH
    J Control Release; 2019 May; 301():176-189. PubMed ID: 30849445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin and its application in drug delivery.
    Sleep D
    Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances of long-acting recombinant protein therapeutics].
    Wei Y; Zhang Z; Lu Y; Cheng Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):360-368. PubMed ID: 29577686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.
    Gebauer M; Skerra A
    Bioorg Med Chem; 2018 Jun; 26(10):2882-2887. PubMed ID: 29102080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.
    Datta-Mannan A; Boyles J; Huang L; Jin ZY; Peariso A; Murphy AT; Ellis B; Douglass N; Norouziyan-Cooper F; Witcher DR
    Biotechnol J; 2019 Mar; 14(3):e1800007. PubMed ID: 29802766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-based drug delivery: harnessing nature to cure disease.
    Larsen MT; Kuhlmann M; Hvam ML; Howard KA
    Mol Cell Ther; 2016; 4():3. PubMed ID: 26925240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for extended serum half-life of protein therapeutics.
    Kontermann RE
    Curr Opin Biotechnol; 2011 Dec; 22(6):868-76. PubMed ID: 21862310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin as a versatile platform for drug half-life extension.
    Sleep D; Cameron J; Evans LR
    Biochim Biophys Acta; 2013 Dec; 1830(12):5526-34. PubMed ID: 23639804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
    Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
    Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
    Unverdorben F; Hutt M; Seifert O; Kontermann RE
    PLoS One; 2015; 10(10):e0139838. PubMed ID: 26430884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
    Lee JY; Park T; Hong E; Amatya R; Park KA; Park YH; Min KA; Jin M; Lee S; Hwang S; Roh GS; Shin MC
    Biomaterials; 2020 Oct; 257():120250. PubMed ID: 32736262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.